This Biotech Is Entering The Clinical Stage With A Psilocin Analog Targeting Cluster Headaches
Portfolio Pulse from Lara Goldstein
Lobe Sciences Ltd. (OTCQB:LOBEF) has started its Phase 1 clinical study on proprietary psilocin analog L-130, aimed at treating Chronic Cluster Headaches (CCH). The study is being conducted in Jordan under the country’s FDA authority. The results of the study, expected to be completed in Q3 2021, will be used to determine L-130 dose levels for an upcoming Phase 2a study in CCH.
June 28, 2023 | 10:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lobe Sciences has begun its Phase 1 clinical study on L-130 for treating Chronic Cluster Headaches. The results, expected in Q3 2021, will guide the upcoming Phase 2a study.
The commencement of the Phase 1 clinical study is a significant milestone for Lobe Sciences. If the study is successful, it could lead to a potential new treatment for Chronic Cluster Headaches, which could significantly boost the company's revenues and profitability. This could have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100